These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

722 related articles for article (PubMed ID: 34635626)

  • 21. Metabolic-associated fatty liver disease and the risk of cardiovascular disease.
    Zhang P; Dong X; Zhang W; Wang S; Chen C; Tang J; You Y; Hu S; Zhang S; Wang C; Wen W; Zhou M; Tan T; Qi G; Li L; Wang M
    Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102063. PubMed ID: 36494073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact.
    Tang SY; Tan JS; Pang XZ; Lee GH
    World J Gastroenterol; 2023 Jan; 29(3):549-560. PubMed ID: 36688021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China.
    Liang Y; Chen H; Liu Y; Hou X; Wei L; Bao Y; Yang C; Zong G; Wu J; Jia W
    J Clin Endocrinol Metab; 2022 Jan; 107(1):88-97. PubMed ID: 34508601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study.
    Han E; Chun HS; Lee YH; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Lee BW; Kang ES; Cha BS; Ahn SH; Kim SU
    J Gastroenterol Hepatol; 2023 Sep; 38(9):1598-1609. PubMed ID: 37321651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identifying inflammatory bowel disease patients at risk of metabolic dysfunction-associated fatty liver disease: usefulness of non-invasive steatosis predictive scores.
    Capela TL; Silva VM; Freitas M; Arieira C; Gonçalves TC; de Castro FD; Magalhães J; Cotter J
    BMC Gastroenterol; 2023 Dec; 23(1):437. PubMed ID: 38093213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
    Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M
    Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma Calprotectin Levels Associate with Suspected Metabolic-Associated Fatty Liver Disease and All-Cause Mortality in the General Population.
    Bourgonje AR; van den Berg EH; Kieneker LM; Nilsen T; Hidden C; Bakker SJL; Blokzijl H; Dullaart RPF; van Goor H; Abdulle AE
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonalcoholic fatty liver disease without overlapping metabolic-associated fatty liver disease and the risk of incident type 2 diabetes.
    Cho Y; Chang Y; Ryu S; Wild SH; Byrne CD
    Liver Int; 2023 Nov; 43(11):2445-2454. PubMed ID: 37387519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibrosis-4 Index Score Predicts Concomitant Coronary Artery Diseases Across the Spectrum of Fatty Liver Disease.
    McNally BB; Rangan P; Wijarnpreecha K; Fallon MB
    Dig Dis Sci; 2023 Sep; 68(9):3765-3773. PubMed ID: 37392337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population.
    Seo JY; Cho EJ; Kim MJ; Kwak MS; Yang JI; Chung SJ; Yim JY; Yoon JW; Chung GE
    J Cachexia Sarcopenia Muscle; 2022 Dec; 13(6):2953-2960. PubMed ID: 36222309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential risk of 23 site-specific incident cancers and cancer-related mortality among patients with metabolic dysfunction-associated fatty liver disease: a population-based cohort study with 9.7 million Korean subjects.
    Chung GE; Yu SJ; Yoo JJ; Cho Y; Lee KN; Shin DW; Kim YJ; Yoon JH; Han K; Cho EJ
    Cancer Commun (Lond); 2023 Aug; 43(8):863-876. PubMed ID: 37337385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between serum 25-hydroxy vitamin D concentrations and mortality among individuals with metabolic dysfunction-associated fatty liver disease: a prospective cohort study.
    Zhang JJ; Yu HC; Li Y; Zhang YB; Geng TT; Lu Q; Liao YF; Guo KQ; Du L; Ruan HL; Yang K; Liu G; Pan A
    Am J Clin Nutr; 2022 Nov; 116(5):1409-1417. PubMed ID: 36107812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MAFLD and NAFLD in the prediction of incident chronic kidney disease.
    Kwon SY; Park J; Park SH; Lee YB; Kim G; Hur KY; Koh J; Jee JH; Kim JH; Kang M; Jin SM
    Sci Rep; 2023 Jan; 13(1):1796. PubMed ID: 36720976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NAFLD and MAFLD independently increase the risk of major adverse cardiovascular events (MACE): a 20-year longitudinal follow-up study from regional Australia.
    Vaz K; Kemp W; Majeed A; Lubel J; Magliano DJ; Glenister KM; Bourke L; Simmons D; Roberts SK
    Hepatol Int; 2024 Aug; 18(4):1135-1143. PubMed ID: 39008030
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic Associated Fatty Liver Disease Increases the Risk of Systemic Complications and Mortality. A Meta-Analysis and Systematic Review of 12 620 736 Individuals.
    Quek J; Ng CH; Tang ASP; Chew N; Chan M; Khoo CM; Wei CP; Chin YH; Tay P; Lim G; Tan DJH; Lim WH; Chan KE; Teng M; Tan E; Tamaki N; Huang DQ; Siddiqui MS; Young DY; Noureddin M; Muthiah MD
    Endocr Pract; 2022 Jul; 28(7):667-672. PubMed ID: 35364328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: A meta-analysis.
    Wen W; Li H; Wang C; Chen C; Tang J; Zhou M; Hong X; Cheng Y; Wu Q; Zhang X; Feng Z; Wang M
    Front Endocrinol (Lausanne); 2022; 13():934225. PubMed ID: 36187109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic dysfunction-associated fatty liver disease is associated with an increase in systolic blood pressure over time: linear mixed-effects model analyses.
    Mori K; Tanaka M; Hosaka I; Mikami T; Endo K; Hanawa N; Ohnishi H; Furuhashi M
    Hypertens Res; 2023 May; 46(5):1110-1121. PubMed ID: 36717630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients.
    Kim MN; Han K; Yoo J; Hwang SG; Zhang X; Ahn SH
    Int J Cancer; 2023 Oct; 153(8):1448-1458. PubMed ID: 37439276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Left Ventricular Diastolic Function and Cardiac Morphology.
    Peng D; Yu Z; Wang M; Shi J; Sun L; Zhang Y; Zhao W; Chen C; Tang J; Wang C; Ni J; Wen W; Jiang J
    Front Endocrinol (Lausanne); 2022; 13():935390. PubMed ID: 35928895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular Disease Risk and Statin Use Among Adults with Metabolic Dysfunction Associated Fatty Liver Disease.
    Yeoh A; Cheung R; Ahmed A; Chitnis AS; Do A; Wong RJ
    Am J Med; 2023 Jul; 136(7):669-676.e1. PubMed ID: 37001720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.